Activaero is the leading company in the field of controlled breathing technologies for inhaled therapeutic ageActivaero is the leading company in the field of controlled breathing technologies for inhaled therapeutic agents. It has two inhalation devices on the market and is in clinical stage development for a pharmaceutical product.
Amakem is using it’s Localized Drug Action platform for the development of kinase inhibitors. The primary focus is on eye disease.
Apitope is an established leader in discovery and development of antigen-specific immunotherapeutic peptides focused on autoimmune diseases.
Biotechnological Enzymatic Catalyse – Bienca – develops, produces and commercializes enzymatic systems for food protection. It is one of the first companies in the world to propose bio-mimicry (technology inspired by nature) for food protection.
Complix is a developer of novel protein therapeutics based on its proprietary Alphabody technology.
Exact Imaging is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists will now be able to visualize areas of interest in the prostate and specifically target biopsies at those areas in addition to performing systematic biopsy protocols.
FF Pharmaceuticals focuses on the development of novel disease-modifying therapeutics for the treatment of inflammatory diseases
Fovea Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative drug products for disabling diseases of the eye.
GenKyoTex is a product-driven biopharmaceutical company dedicated to the development of innovative therapeutics blocking the source of production of oxygen radicals in a specific manner to meet unmet medical need.
IPO on Euronext
Genomic Vision has developed a pioneering approach for genomic analyses called molecular combing technology, which allows the direct visualization of single DNA molecules. The company uses this approach to detect quantitave and qualitative changes in the genome linked to disease.
The goal of Humedics is to improve the diagnostic and prognostic assessment of severe liver diseases and to support doctors in improving and providing a more secure basis for their treatment decisions
Pluriomics focusses on the development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells, the company develops highly functional cell types like the Pluricyte Cardiomyocytes which are used in combination with phenotypic assays to deliver high quality results.
New identity reflects Ogeda’s successful transition to GPCR drug discovery & development
Ogeda develops drugs to validated GPCR targets in the areas of women’s health, inflammation and neurodegenerative diseases.
Omeicos is developing novel small molecule drugs for the treatment and prevention of atrial fibrillation using a first-in-class novel metabolite of omega 3 fatty acids.
ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets.
Promethere Biosciences is an innovative stem cell therapy company and a spin-off the Université Catholique de Louvain. It’s mission is to develop novel cell-based products to treat incurable liver disease.
Skyline Diagnostics is a molecular diagnostic company developing tests for the classification of patients with blood cancers. The tests are standardized, automated and easy to use, thus allowing for a rapid, personalized treatment of each patient.
SOFTHALE is developing innovative drug/device products for the treatment mainly of asthma and COPD
Trinean is a developer and producer of nanoliter spectrophotometers and consumables for the scientific market.
The company develops Encage TM, a radio frequency ablation device for treating prostate cancer.
Voluntis develops state-of-the-art companion software to accompany and enhance a specific medical device or indication in the field of diabetes, coagulation and haemophilia.